4131 - 4140 of 9038 Results
Title
Year
-
OPENTitle: Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection: Evidence from Parkinson’s disease patients with defined cholinergic lossesJournal Name: NeuroImagePublisher: Elsevier BVVol: 149Issue #:Start Page: 295End Page: 304Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neuroimage.2017.02.006Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/5386784Citation Count: 50
-
OPENTitle: Gut microbiome-derived tryptophan metabolites predict relapse in alcohol use disorderJournal Name: Brain, Behavior, and ImmunityPublisher: Elsevier BVVol: 131Issue #:Start Page: 106161End Page: 106161Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.bbi.2025.106161Best OA location URL: https://doi.org/10.1016/j.bbi.2025.106161Citation Count: 1
-
OPENTitle: Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson diseaseJournal Name: Annals of Clinical and Translational NeurologyPublisher: WileyVol: 2Issue #: 10Start Page: 949End Page: 959Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/acn3.246Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acn3.246Citation Count: 202
-
OPENTitle: A molecular glue for PRKN/parkinJournal Name: AutophagyPublisher: Informa UK LimitedVol: 21Issue #: 3Start Page: 689End Page: 690Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1080/15548627.2024.2443232Best OA location URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11849950/pdf/KAUP_21_2443232.pdfCitation Count: 2
-
OPENTitle: mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cellsJournal Name: Disease Models & MechanismsPublisher: The Company of BiologistsVol: 12Issue #: 10Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1242/dmm.038596Best OA location URL: https://doi.org/10.1242/dmm.038596Citation Count: 72
- Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats2016RESTRICTEDTitle: Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian ratsJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 110Issue #:Start Page: 125End Page: 134Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2016.07.025Citation Count: 29
-
OPENTitle: FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage diseaseJournal Name: NeuroImage: ClinicalPublisher: Elsevier BVVol: 20Issue #:Start Page: 572End Page: 579Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.nicl.2018.08.006Best OA location URL: https://doi.org/10.1016/j.nicl.2018.08.006Citation Count: 92
- Effects of augmenting cholinergic neurotransmission on balance in Parkinson's disease2019RESTRICTEDTitle: Effects of augmenting cholinergic neurotransmission on balance in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 69Issue #:Start Page: 40End Page: 47Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2019.10.022Citation Count: 27
-
OPENTitle: Magnetoelectric nanoparticle technology for mitigating motor deficits in Parkinsonian miceJournal Name: Brain StimulationPublisher: Elsevier BVVol: 18Issue #: 5Start Page: 1551End Page: 1560Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.brs.2025.08.008Best OA location URL: https://doi.org/10.1016/j.brs.2025.08.008Citation Count: 3
- Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study2018RESTRICTEDTitle: Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 18Issue #: 2Start Page: 165End Page: 176Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(18)30391-0Citation Count: 107